ogasawara sadahisa 小笠原定久

… Alternative Names

Ogasawara Sadahisa 小笠原定久

Less

Researcher Number	20749155
Other IDs
Affiliation (Current)	2026: 千葉大学, 大学院医学研究院, 講師
Affiliation (based on the past Project Information) *help	2023 – 2024: 千葉大学, 大学院医学研究院, 講師 2022 – 2023: 千葉大学, 医学部附属病院, 講師
Review Section/Research Field	Principal Investigator Basic Section 53010:Gastroenterology-related Except Principal Investigator Basic Section 54040:Metabolism and endocrinology-related / Basic Section 53010:Gastroenterology-related
Keywords	Principal Investigator 腫瘍微小環境 / 腫瘍抗原認識 / 肝硬変 / 慢性肝炎 / 免疫療法 / 免疫チェックポイント阻害剤 / 腫瘍免疫微小環境 / CD8+T細胞 / 肝細胞癌 Except Principal Investigator 肥満症 … More / 選択的インスリン抵抗性 / PPARα / FoxO1 / 脂肪合成 / 糖新生 / 転写因子 / インスリン抵抗性 / NK細胞 / Non-inflamed type / Inflamed type / 免疫サブクラス / 腫瘍免疫微小環境 / 複合免疫療法 / 腫瘍浸潤リンパ球 / 制御性T細胞 / 細胞傷害性T細胞 / PD-1 / ベバシズマブ / アテゾリズマブ / 肝細胞癌 Less

Development of all-round combined immunotherapy for advanced hepatocellular carcinoma
- Principal Investigator
  
  加藤直也
- Project Period (FY)
  2024
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Chiba University
Deciphering haptic glucose regulatory mechanism through liver FoxO1 PPARA in liver-fat axis and its clinical application
- Principal Investigator
  
  北本匠
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 54040:Metabolism and endocrinology-related
- Research Institution
  Chiba University
Analysis of tumor antigen recognition of T cell accumulated in the underlying liver of hepatocellular carcinomaPrincipal Investigator
- Principal Investigator
  
  Ogasawara Sadahisa
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Chiba University

All 2025 2024 2023 2022

All Journal Article Presentation

[Journal Article] MEGF6 knockdown ameliorates lenvatinib-induced muscle differentiation suppression and enhances the antitumor effect of lenvatinib on hepatocellular carcinoma2025
- Author(s)
  Qiang Na、Ao Junjie、Nakamura Masato、Katayama Keichi、Zhang Jiaqi、Kogure Tadayoshi、Ogawa Keita、Kanzaki Hiroaki、Kojima Ryuta、Koroki Keisuke、Kobayashi Kazufumi、Inoue Masanori、Kanogawa Naoya、Kiyono Soichiro、Nakagawa Ryo、Kondo Takayuki、Ogasawara Sadahisa、Nakamoto Shingo、Muroyama Ryosuke、Kato Jun、Kato Naoya
- Journal Title
  
  Biochemical Pharmacology
  
  Volume: 235 Pages: 116829-116829
- DOI
  10.1016/j.bcp.2025.116829
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K27577, KAKENHI-PROJECT-22K08049
[Journal Article] Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma2025
- Author(s)
  Yonemoto Takuya、Ogasawara Sadahisa、et al.
- Journal Title
  
  Hepatology Research
  
  Volume: 55 Issue: 5 Pages: 718-729
- DOI
  10.1111/hepr.14160
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22K08049
[Journal Article] Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy2025
- Author(s)
  Miwa Chihiro、Ogasawara Sadahisa、Yonemoto Takuya、Yumita Sae、Okubo Tomomi、Nakagawa Miyuki、Koroki Keisuke、Inoue Masanori、Kanogawa Naoya、Nakamura Masato、Kondo Takayuki、Nakamoto Shingo、Itokawa Norio、Atsukawa Masanori、Itobayashi Ei、Kato Naoya
- Journal Title
  
  Cancer Medicine
  
  Volume: 14 Issue: 5
- DOI
  10.1002/cam4.70642
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K27577
[Journal Article] Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy2024
- Author(s)
  Inoue Masanori、Ogasawara Sadahisa、Kato Naoya、et al.
- Journal Title
  
  Liver Cancer
  
  Volume: 14 Pages: 8-18
- DOI
  10.1159/000539380
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K27577, KAKENHI-PROJECT-24K18964
[Journal Article] Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)2024
- Author(s)
  Kobayashi Kazufumi、Ogasawara Sadahisa、Kato Naoya、et al.
- Journal Title
  
  Investigational New Drugs
  
  Volume: 42 Issue: 4 Pages: 394-404
- DOI
  10.1007/s10637-024-01441-3
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K27577
[Journal Article] Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis2024
- Author(s)
  Ozaki Tomomi、Yumita Sae、Ogasawara Sadahisa、Kato Naoya、et al.
- Journal Title
  
  Hepatology Research
  
  Volume: 55 Issue: 2 Pages: 291-297
- DOI
  10.1111/hepr.14088
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K27577
[Journal Article] Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis2024
- Author(s)
  Ao Junjie、Qiang Na、Kanzaki Hiroaki、Nakamura Masato、Kakiuchi Risa、Zhang Jiaqi、Kojima Ryuta、Koroki Keisuke、Inoue Masanori、Kanogawa Naoya、Nakagawa Ryo、Kondo Takayuki、Ogasawara Sadahisa、Nakamoto Shingo、Muroyama Ryosuke、Kato Jun、Kato Naoya
- Journal Title
  
  American Journal of Physiology-Cell Physiology
  
  Volume: 327 Issue: 4 Pages: C1150-C1161
- DOI
  10.1152/ajpcell.00511.2024
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K27577, KAKENHI-PROJECT-22K08049
[Journal Article] Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma2024
- Author(s)
  Fujiwara Kisako、Kondo Takayuki、Ogasawara Sadahisa、Kato Naoya、et al.
- Journal Title
  
  Journal of Gastroenterology
  
  Volume: 59 Issue: 6 Pages: 515-525
- DOI
  10.1007/s00535-024-02097-9
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K27577, KAKENHI-PROJECT-24K18933
[Journal Article] A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: The LAUNCH study.2023
- Author(s)
  Kobayashi K, Ogasawara S, Kato N, et al.
- Journal Title
  
  Clin Cancer Res
  
  Volume: 55 Issue: 23 Pages: 1072-1080
- DOI
  10.1158/1078-0432.ccr-23-1462
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K27577
[Journal Article] Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens2023
- Author(s)
  Ishino Takamasa、Kawashima Shusuke、Tanji Etsuko、Ueno Toshihide、Ueda Youki、Ogasawara Sadahisa、Sato Kazuhito、Mano Hiroyuki、Ishihara Soichiro、Kato Naoya、Kawazu Masahito、Togashi Yosuke
- Journal Title
  
  British Journal of Cancer
  
  Volume: 128 Issue: 6 Pages: 1166-1175
- DOI
  10.1038/s41416-023-02165-6
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K08049, KAKENHI-PROJECT-22K19459, KAKENHI-PROJECT-22K15472, KAKENHI-PROJECT-20H03694, KAKENHI-PROJECT-21H02772, KAKENHI-PROJECT-21K20859, KAKENHI-PROJECT-21K12117
[Journal Article] Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.2023
- Author(s)
  Kondo T, Ogasawara S, Kato N et al.
- Journal Title
  
  Sci Rep
  
  Volume: 13 Issue: 1 Pages: 11524-11524
- DOI
  10.1038/s41598-023-38377-2
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K27577
[Journal Article] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice2023
- Author(s)
  Yumita S, Ogasawara S, Nakagawa M, Maruta S, Okubo T, et al.
- Journal Title
  
  BMC Gastroenterology
  
  Volume: 23 Issue: 1 Pages: 101-101
- DOI
  10.1186/s12876-023-02731-5
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K08049, KAKENHI-PROJECT-23K27577
[Journal Article] Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.2023
- Author(s)
  Kanzaki H, Ogasawara S, Kato N, et al.
- Journal Title
  
  Drugs Real World Outcomes
  
  Volume: 10 Issue: 4 Pages: 513-520
- DOI
  10.1007/s40801-023-00379-x
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23K27577
[Journal Article] Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.2023
- Author(s)
  Kanogawa N, Ogasawara S, Kato N, et al.
- Journal Title
  
  BMC Gastroenterol
  
  Volume: 23 Issue: 1 Pages: 70-70
- DOI
  10.1186/s12876-023-02674-x
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K27577
[Journal Article] Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis2022
- Author(s)
  Ozeki Yusuke,... Tawada Akinobu,...Kato Naoya
- Journal Title
  
  International Journal of Clinical Oncology
  
  Volume: 27 Issue: 9 Pages: 1459-1466
- DOI
  10.1007/s10147-022-02195-9
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K08412, KAKENHI-PROJECT-20K08561, KAKENHI-PROJECT-21K06881, KAKENHI-PROJECT-22K08049
[Journal Article] Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real‐world practice2022
- Author(s)
  Nakagawa Miyuki、Inoue Masanori、Ogasawara Sadahisa、et al.
- Journal Title
  
  Cancer
  
  Volume: 129 Issue: 4 Pages: 590-599
- DOI
  10.1002/cncr.34559
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] Impact of Vascular Involvement on Treatment with Checkpoint Inhibitors2024
- Author(s)
  Ogasawara Sadahisa
- Organizer
  The 14th Asia-Pacific Liver Cancer Expert Meeting
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] Systemic therapies for advanced hepatocellular carcinoma in Japanese real-world practice2024
- Author(s)
  Sadahisa Ogasawara
- Organizer
  第21回日本臨床腫瘍学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] Exploring the efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes2024
- Author(s)
  Kanzaki H, Ishino T, Ogasawara S, Yumita S, Nakagawa M, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakamoto S, Takayashiki T, Lin J, Kawazu M, Komuta M, Ikeda J, Ohtsuka M, Togashi Y, Kato N
- Organizer
  AACR ANNUAL MEETING 2024
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] Harnessing the Power of Real-World Data to Address Clinical Challenges in Systemic Therapy for Advanced Hepatocellular Carcinoma2024
- Author(s)
  Ogasawara Sadahisa
- Organizer
  APASL Oncology Chiba 2024
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] Tumor microenvironment in hepatocellular carcinoma and its optimal treatment approach2024
- Author(s)
  Sadahisa Ogasawara
- Organizer
  The 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] How Can We Boost T Cell Responses during Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma?2023
- Author(s)
  Sadahisa Ogasawara
- Organizer
  The Liver Week 2023
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] A Prospective Study to Assess the Safety and Efficacy of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma Aiming to Maximise Its Potential in Current Clinical Practice2023
- Author(s)
  Kobayashi K, Ogasawara S, Kato N, et al.
- Organizer
  APASL Oncology 2023
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K27577
[Presentation] A Randomized Phase II Trial to Assess Safety and Efficacy of Regorafenib in Patients with Advanced Hepatocellular Carcinoma who were not Included in the RESORCE Trial: REGAIN Trial2023
- Author(s)
  Koroki K, Ogasawara S, Kato N, et al.
- Organizer
  APASL Oncology 2023
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K27577
[Presentation] A Prospective Study to Assess the Safety and Efficacy of Ramucirumab in Advanced Hepatocellular Carcinoma Patients in Japanese Real-world Practice: R-evolution Study2023
- Author(s)
  Kobayashi K, Ogasawara S, Kato N, et al.
- Organizer
  APASL Oncology 2023
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K27577
[Presentation] Differentiation of AST/ALT Elevation during Immunotherapy in Patients with Advanced Hepatocellular Carcinoma and Other Cancers2023
- Author(s)
  Izai R, Ogasawara S, Kato N, et al.
- Organizer
  APASL Oncology 2023
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-23K27577
[Presentation] Advancing towards the future of hepatocellular carcinoma treatment: Latest clinical research trends and prospects2023
- Author(s)
  Sadahisa Ogasawara
- Organizer
  第82回日本癌学会
- Invited
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] 複合免疫療法の実臨床におけるインパクトと今後の課題2022
- Author(s)
  小笠原定久、叶川直哉、加藤直也
- Organizer
  第58回日本肝臓学会総会
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] 本邦の進行肝細胞癌治療における複合免疫療法のインパクト2022
- Author(s)
  小笠原定久、叶川直哉、加藤直也
- Organizer
  JDDW 2022
- Data Source
  KAKENHI-PROJECT-22K08049
[Presentation] 進行肝細胞癌における複合免疫療法のインパクトとその臨床的課題2022
- Author(s)
  小笠原定久、叶川直哉、加藤直也
- Organizer
  第60回日本癌治療学会学術集会
- Data Source
  KAKENHI-PROJECT-22K08049

1. 冨樫庸介 (80758326)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
2. 加藤直也 (90313220)

# of Collaborated Projects: 1 results

# of Collaborated Products: 15 results
3. 北本匠 (90916173)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. 松本泰典 (80738831)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. 黒田正幸 (00253005)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. 前澤善朗 (80436443)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 横手幸太郎 (20312944)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 太和田暁之

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

ogasawara sadahisa 小笠原 定久

Ogasawara Sadahisa 小笠原 定久

Research Projects

Research Products

Co-Researchers

Development of all-round combined immunotherapy for advanced hepatocellular carcinoma

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Deciphering haptic glucose regulatory mechanism through liver FoxO1 PPARA in liver-fat axis and its clinical application

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Analysis of tumor antigen recognition of T cell accumulated in the underlying liver of hepatocellular carcinomaPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] MEGF6 knockdown ameliorates lenvatinib-induced muscle differentiation suppression and enhances the antitumor effect of lenvatinib on hepatocellular carcinoma2025

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma2025

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy2025

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: The LAUNCH study.2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice2023

Author(s)

ogasawara sadahisa 小笠原定久

Ogasawara Sadahisa 小笠原定久